Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03301792
Other study ID # 201707118; 201906068 (1001)
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 14, 2017
Est. completion date August 31, 2025

Study information

Verified date December 2023
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators primary objective is to conduct a randomized trial to determine the effect of diabetes group prenatal care on glycemic control and postpartum weight retention in women with type 2 diabetes and gestational diabetes.


Description:

Long term, the investigator aims to test the central hypothesis that group prenatal care, compared to traditional prenatal care, will improve, 1.) glycemic control and, 2.) postpartum weight retention in women with type 2 and gestational diabetes. The objective of this proposal is to conduct a randomized trial in two phases to determine the effect of Diabetes Group Care (GC) on glycemic control in pregnant women with T2DM and GDM (Antepartum Phase) and the impact on postpartum weight retention (Postpartum Phase).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 117
Est. completion date August 31, 2025
Est. primary completion date August 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. English speaking 2. Type 2 diabetes OR gestational diabetes diagnosed by 2-step method(1) OR likely pre-existing Type 2 diabetes with one of the following during pregnancy and </= 34 weeks: 1. 1 hour glucose challenge test >/= 185mg/dL OR 2. A1c >/= 6.5% OR 3. Fasting plasma glucose > 126mg/dL (2) 3. Ability to attend group prenatal visit at specified days and times 4. Willingness to be randomized at 22 weeks 0 days-34 weeks 0 days OR initial visit between 24 weeks 0 days-34 weeks 0 days 5. Ability to give informed consent Exclusion Criteria: 1. Prior participation in diabetes group care 2. Type 1 Diabetes 3. Multiple gestation 4. Major fetal anomaly 5. Serious medical co-morbidity necessitating more care than can be safely provided in group setting, as deemed by medical provider. 6. Serious psychiatric illness including schizophrenia necessitating more care than can safely be provided in group setting, as deemed by medical provider.

Study Design


Intervention

Behavioral:
Group prenatal care
Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.

Locations

Country Name City State
United States Washington University in St. Louis Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Diabetes Group Care on maternal glycemic control Determine the effect of Diabetes Group care on maternal glycemic control by randomizing women to Diabetes group care or traditional care and compare 1) Mean fasting blood glucose, 2) Mean 1-hour post-prandial blood glucose, and 3) Hemoglobin A1c at delivery, 4-12 weeks postpartum, six months postpartum, one year postpartum Initial study visit (22-34 weeks) through one year postpartum
Primary Effect of Diabetes Group Care on postpartum weight retention Determine the impact of Diabetes Group care on postpartum weight retention in pounds based on postpartum weight retention at one year. Average weight retention will be compared at 4-12 weeks, six months postpartum, and one year postpartum. Pre-pregnancy weight (up to 6 months prior to initial visit) through one year postpartum
Secondary Completion of self-care activities Determine the effect of Diabetes Group care on maternal diabetes self-care activities by using the Diabetes Self-care Activities Scale (a measure of the number of days during the prior week in which the subject followed diet, exercise, blood sugar testing, and medication adherence recommendations) 37-39 weeks gestation
Secondary Effect of Diabetes Group Care on number of blood glucose values Determine the effect of Diabetes Group care by measuring the percentage of recommended blood glucose values entered on logs since initial study visit Initial study visit (22-34 weeks) through 39 weeks gestation
Secondary Maternal Antepartum Compliance Determine the effect of Diabetes Group Care on maternal antepartum compliance by assessing the number of prenatal appointments attended Initial study visit (22-34weeks) through 4-12 weeks postpartum
Secondary Maternal Antepartum Physical Activity/Eating Behavior Determine the effect of Diabetes Group Care on maternal antepartum physical activity/eating behavior using a physical activity/eating behavior questionnaire Initial study visit (22-34weeks) through one year postpartum
Secondary Maternal Antepartum Weight Gain Determine the effect of Diabetes Group Care on maternal antepartum weight gain in pounds Initial study visit (22-34weeks) through delivery
Secondary Maternal Intrapartum Mode of Delivery Determine the effect of Diabetes Group Care on maternal intrapartum mode of delivery by assessing whether infant was delivered spontaneously, using vacuum, forceps, or cesarean. Delivery through 4-12 weeks postpartum
Secondary Maternal Intrapartum Hypertensive Disease of Pregnancy Determine the effect of Diabetes Group Care on maternal intrapartum hypertensive disorders of pregnancy by assessing whether they develop gestational hypertension, preeclampsia, or eclampsia. Delivery through 4-12 weeks postpartum
Secondary Maternal Postpartum Readmission Determine the effect of Diabetes Group Care on maternal postpartum readmission by assessing number of maternal hospital readmissions within 6 weeks postpartum. 4-12 weeks postpartum
Secondary Maternal Postpartum Visit Attendance Determine the effect of Diabetes Group Care on maternal postpartum visit attendance by assessing whether she attends a postpartum visit between 4-12 weeks postpartum. 4-12 weeks postpartum
Secondary Maternal Postpartum Glucose Testing Determine the effect of Diabetes Group Care on maternal postpartum glucose testing 4-12 weeks postpartum
Secondary Maternal Postpartum Breastfeeding Determine the effect of Diabetes Group Care on maternal postpartum breastfeeding using a breastfeeding scale questionnaire 4-12 weeks postpartum, six months postpartum, one year postpartum
Secondary Maternal Postpartum Contraception Determine the effect of Diabetes Group Care on maternal postpartum contraception choices by assessing use of short acting reversible contraception, long acting reversible, and sterilization. 4-12 weeks postpartum, six months postpartum, one year postpartum
Secondary Neonatal Birthweight Determine the effect of Diabetes Group Care on neonatal birth weight in grams delivery admission
Secondary Neonatal Gestational Age Determine the effect of Diabetes Group Care on neonatal gestational age at delivery delivery admission
Secondary Neonatal APGAR Scores Determine the effect of Diabetes Group Care on neonatal APGAR score delivery admission
Secondary Neonatal Adiposity and body composition Determine the effect of Diabetes Group Care on neonatal adiposity and body composition by air displacement plethysmography within 1 week of delivery. Skin fold thickness of triceps, subscapular, ilium, and thigh at delivery, six weeks, six months, one year postpartum. delivery admission through one year postpartum
Secondary Neonatal body measurements-Weight Determine the effect of Diabetes Group Care on neonatal weight in grams delivery through one year postpartum
Secondary Neonatal body measurements-Length Determine the effect of Diabetes Group Care on neonatal length in centimeters delivery through one year postpartum
Secondary Neonatal body measurements-Head Circumference Determine the effect of Diabetes Group Care on neonatal head circumference in centimeters delivery through one year postpartum
Secondary Neonatal NICU Admission Determine the effect of Diabetes Group Care on neonatal NICU admission delivery admission
Secondary Neonatal Hypoglycemia Determine the effect of Diabetes Group Care on neonatal hypoglycemia delivery admission
Secondary Neonatal Outcomes Determine the effect of Diabetes Group Care on neonatal hematocrit delivery admission
Secondary Neonatal Jaundice Determine the effect of Diabetes Group Care on neonatal jaundice delivery admission
Secondary Neonatal Stillbirth Rates Determine the effect of Diabetes Group Care on neonatal stillbirth rates delivery admission
Secondary Psychosocial Stress Determine the effect of Diabetes Group Care on psychosocial stress by comparing Cohen's Perceived Stress at study entry visit, last study visit (37-39 weeks) and 4-12 weeks postpartum, six months postpartum, one year postpartum. Initial study visit (22-34weeks) through one year postpartum
Secondary Psychosocial Stress Determine the effect of Diabetes Group Care on psychosocial stress by comparing life events checklist at study entry visit and six months postpartum Initial study visit (22-34weeks) and six months postpartum
Secondary Psychosocial Distress Determine the effects of Diabetes Group Care on psychosocial stress by comparing Pregnancy Distress questionnaire at study entry, last study visit (37-39 weeks), and 4-12 weeks postpartum Initial study visit (22-34 weeks) through 4-12 weeks postpartum
Secondary Psychosocial Anxiety Determine the effects of Diabetes Group Care on psychosocial stress by comparing GAD-7 at study entry, last study visit (37-39weeks) and 4-12 weeks postpartum, six months postpartum, one year postpartum. Initial study visit (22-34weeks) through one year postpartum
Secondary Psychosocial Depression Determine the effects of Diabetes Group Care on depression by comparing the Edinburgh Postnatal Depression Scale at study entry, last study visit (37-39 weeks) and 4-12 weeks postpartum, six months postpartum, one year postpartum Initial study visit (22-34weeks) through 1 year postpartum
Secondary Psychosocial Stress and Depression Determine the effects of Diabetes Group Care on stress and depression by measuring alcohol or drug use in first year postpartum Delivery through postpartum
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A